FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549
raoriirigiori,	D.O.	_00.0

STATEMENT	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-02									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person* Simon Barry J.						2. Issuer Name and Ticker or Trading Symbol ImmunityBio, Inc. [IBRX]									Relationship of Reporting F (Check all applicable) X Director			g Pers	son(s) to Iss			
(Last)	,	,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/31/2024										Officer below)	(give title		Other (s below)	specify		
C/O IMMUNITYBIO, INC. 3530 JOHN HOPKINS COURT						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person							
(Street) SAN DII	EGO C.	A	92121													Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instr							int to a									
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3) 2. Trans Date (Month/I				action 2A. Deemed Execution Date, if any (Month/Day/Year)		, [Transaction Disposed Code (Instr. 5)		ities Acquired (A) o d Of (D) (Instr. 3, 4 a			Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership						
								[Code	v	Amount	(A) o (D)	r Pri	се	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common Stock 01/31						1/2024			М		57,200 A			\$ <mark>0</mark>	3,145,855			D				
Common	Stock			01/3	1/2024 F 22,094 D \$			\$	\$3.36 3,123,761 D													
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)				Date,		ransaction of ode (Instr. Derivative			Exp	6. Date Exercisable and Expiration Date (Month/Day/Year) (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Sect (Instr. 3 and 4)			ies g Secur	Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title	Amou or Numb of Share	er							
Restricted Stock Units	(1)	01/31/2024			M			57,200		(2)		(2)	Common Stock	57,2	00	\$0	0		D			

Explanation of Responses:

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- 2. Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 57,199 of the RSUs subject to the award vested on September 1, 2023 and 57,200 of the RSUs subject to the award vested on January 31, 2024.

Remarks:

/s/ Jason Liljestrom, as 02/02/2024 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.